ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Explainable Plasma Proteomics-Based Machine Learning for Osteoporosis Diagnosis, Prognosis, and Protein Biomarker Discovery in the UK Biobank.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteoporosis (OP) is often underdiagnosed, highlighting the need for tools that can both detect existing disease and predict future risk; large-scale plasma proteomics combined with explainable machine learning enables integrated diagnostic and prognostic modeling while prioritizing clinically relevant protein markers. This study aims to develop and validate an explainable plasma proteomics machine-learning framework for osteoporosis diagnosis, future risk prediction, and biomarker discovery. We further tested whether a combined marker panel could distinguish normal, prevalent OP, and future incident OP states from baseline samples. Using UK Biobank plasma proteomic data, we established SPX-OP, which separately models prevalent OP and incident OP based on Extreme Gradient Boosting (XGBoost) and SHapley Additive exPlanations (SHAP), and then evaluates whether the union of diagnostic and prognostic markers supports integrated baseline stratification. In the experiments, both the diagnostic and prognostic XGBoost models showed robust discrimination for osteoporosis status and future risk, respectively. SHAP-derived protein markers, including FSHB, ADIPOQ, SOST, COL9A1, and CHAD, were linked to osteoporosis and enriched in bone-related pathways involving bone development and remodeling, extracellular matrix organization, and inflammatory processes. Using only these SHAP-selected protein markers, the XGBoost model outperformed the full-proteome models and provided robust, simultaneous diagnostic and prognostic prediction of osteoporosis. In summary, this work transforms high-dimensional proteomic data into interpretable marker sets, paving the way for improved risk stratification and further validation of plasma protein biomarkers in osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.